APOA2 and hepatocellular carcinoma: In our quest towards the determination of novel biomarkers that will define HCC at very early stages, our evidence suggests that a combined tool of three markers (miR-200b, APOA2 and APOC3) could diagnose HCC at very early stages accurately and with high sensitivity.